Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.
Mr. Sitar became our Chief Financial Officer in July 2019. Most recently he served as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community, from April 2017 to November 2018. Previously, he served as the Chief Financial Officer of Cancer Genetics, Inc. (Nasdaq: CGIX), a company focused on precision medicine for oncology, from March 2014 until February 2017. Prior to his service at Cancer Genetics, he served from January 2010 to December 2013 as the Chief Financial Officer-New Business of Healthagen, an Aetna company offering health products and services, and served as Chief Financial Officer of ActiveHealth Management from August 2010 to December 2012. From April 2001 to May 2010, he served as Executive Vice President and Chief Financial Officer of Cadent Holdings, Inc., a privately held company that provided three-dimensional digital scanning services for dentists and orthodontists. From August 1998 to April 2001, Mr. Sitar served as Chief Financial Officer and Treasurer of MIM Corporation, now BioScrip, Inc., a publicly traded specialty pharmaceutical and pharmacy benefit management service provider. From May 1996 to August 1998, Mr. Sitar was the Vice President of Finance for Vital Signs, Inc., a publicly traded manufacturer and distributor of single use medical products, which is now part of GE Healthcare . From June 1993 to April 1996, Mr. Sitar was the Controller of Zenith. From 1983 through July 1993, he was with Coopers & Lybrand, a public accounting firm. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey. Mr. Sitar was the 2015 NJBIZ CFO of the Year.
Dr. Griffin became our chief medical officer in February 2019. Previously, Dr. Griffin served as executive vice president and chief medical officer of Synergy Pharmaceuticals from January 2015 through November 2018, and senior vice president and chief medical officer May 2013 through January 2015. From March 2012 to April 2013, Dr. Griffin served as chief medical officer and senior vice president of development at ImmusanT, Inc. From March 2009 until January 2012, Dr. Griffin served as associate vice president, clinical development and head of external innovation at Sanofi-Aventis (now Sanofi). He is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women’s Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, and a private practice in New York.
Dr. Appajosyula helped shape the strategy to create 9 Meters Biopharma Inc. (Nasdaq: NMTR) through targeted transactions to create a diversified pipeline and accessing the public capital markets. At 9 Meters, he is responsible for corporate development including portfolio strategy, in-licensing transactions and alliances for the company’s core assets as well as monetization of non-core assets. Prior to joining 9 Meters, Sireesh spent about 8 years at Salix Pharmaceuticals in various roles of increasing responsibility in medical affairs, product commercialization and business development culminating in Salix’s acquisition for $16 billion by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in medical affairs and commercial roles at Amgen, Critical Therapeutics and Aventis (now Sanofi). Sireesh holds a Doctor of Pharmacy degree from the Ernest Mario College of Pharmacy at Rutgers University in New Jersey.
Dr. Barak’s career has focused on the integration of clinical medicine, basic research, and pharmaceutical development. He served as an attending physician in the department of internal medicine at Beilinson Hospital for 10 years. Dr. Barak began engaging in drug development driven by feedback received from patients regarding shortcomings in available treatment options. Nir served as CSO and Founder of Obecure Ltd. — a company focused on re-purposing Betahistine as an anti-obesity agent. In 2008 after learning from patients of the dearth of treatment options for ano-rectal diseases, he founded RDD Pharma. Under Nir’s leadership, RDD has attracted significant investment from OrbiMed Advisors. — a multinational private equity fund. Dr. Barak earned his MD from the Sackler School of Medicine, Tel-Aviv University, and is Board Certified in Internal Medicine and Clinical Nutrition.
Dr. Bryant became vice president of medical affairs for 9 Meters in February 2021. He has 25 years of pharmaceutical, biotechnology, and medical device industry experience including the development and launch of more than twelve new medicines in GI, hepatology, oncology, respiratory, infectious and rare diseases. Recently, he served as vice president of medical affairs for Eiger Biopharmaceuticals and prior he played a key role at Bayer Pharmaceuticals working with US payors and healthcare decision-makers as deputy director of data generation and outcomes research. As the director of medical affairs at Theravance Biopharma, he was appointed as the medical affairs launch leader as part of a partnership with Mylan. At his 10-year tenure at Salix Pharmaceuticals, he was director of medical science liaisons, where he led the team until its acquisition by Valeant Pharmaceuticals (now part of Bausch Health). He has held various medical affairs roles of increasing responsibility at InterMune, MicroScan (now part of Beckman Coulter), and LifeScan (formerly Johnson & Johnson). Dr. Bryant is an Assistant Clinical Professor at UCSF and serves on the UCSF alumni board of governors. He earned a Bachelor of Science degree from Oregon State University and a Doctor of Pharmacy degree from UCSF and completed a specialty residency in Managed Care Pharmacy at Blue Shield of California.